Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets - GBI Research Reports

Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets

Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets - GBI Research Reports
Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets
Published Jan 31, 2011
296 pages — Published Jan 31, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research has released its latest research Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets, which essentially provides insights into diabetes therapeutics sales and price forecasts until 2016. The report also examines the global diabetes therapies treatment usage patterns. The report covers the key geographies of the US, the top five countries in the European region and Japan. Insights into the diabetes research and development pipeline and the potential future blockbusters by 2016 are included. The report provides an in-depth analysis of HIV, Hepatitis, Herpes and Influenza therapeutic indications, and includes market forecasts and treatment usage patterns for these two therapeutic indications. The report also explores the competitive landscape, including benchmarking for the top companies in the market. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving diabetes therapies is also presented.

According to the study done by GBI Research, the HIV market is a growing market dominated by the US. The growth rate is likely to decline from 2012 onwards due to the impact of patent expiry of key drugs. However, migration to new branded drugs is likely to minimize the impact of generics, which currently account for approximately 8% of the market. The global HIV therapeutics market is expected to grow at a CAGR of 4.5% between 2008 and 2015.

Scope

- Data and analysis on HIV, Hepatitis, Herpes and Influenza therapeutics market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the diabetes therapeutics market from 2001 to 2009, with forecasts to 2016.
- Market Data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Key drivers and restraints that have had a significant impact on the market.
- Competitive landscape of the global antivirals therapeutics market including top companies benchmarking. The key companies studied in this report are Novo Nordisk, Sanofi-Aventis, Takeda Pharmaceuticals, Merck, GlaxoSmithKline, Roche, Bristol Myers Squibb and Gilead.

Reasons to buy

- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.

  
Source:
Document ID
GBIHC052MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents512
  List of Tables104
  List of Figures143
Global Antivirals Market: Introduction171
  GBI Research Report Guidance171
Global HIV Therapeutics Market: Overview182
  Disease Overview181
  Market Overview191
Global HIV Therapeutics Market: Market Characterization2019
  Market Forecasts201
  Annual Cost of Therapy212
  Usage Patterns231
    Diseased Population232
    Treatment Seeking Population252
    Diagnosis Population272
    Prescription Population292
    Usage Patterns312
    Geographical Distribution331
  HIV Therapeutics Market: Drivers and Restraints341
  Market Drivers341
    Increase in Awareness Levels of Disease Progression will Lead to Increase in Treatment Seeking and Diagnosed Population341
      Awareness in the US341
      Awareness in Europe341
      Awareness in Japan351
    New Product Launches with Better Efficacy will Drive the Market By Increasing Uptake351
    Increase in Drug Prices will Be a Key Driver for the Market by Driving Growth in the Next Few Years and Lowering the Impact of Generics361
      Inflation and Drug Prices361
      HIV Therapy and Switch to New Drugs361
  Market Restraints371
    Patent Expirations and the Subsequent Entry of Generics will Impact the Market Negatively as Some People will Move to Generic Versions371
    Social Stigma Associated with HIV Leads to Low Rate of Treatment Seeking Thus Impacting the Overall Customer Base381
    Rigorous and Complex Treatment Regimes for Most HIV Therapies Result in Poor Patient Compliance Leading to a Reduction in Drug Volumes381
Global HIV Therapeutics Market: The US Market3912
  Market Forecasts392
  Annual Cost of Therapy411
  Usage Patterns421
    Diseased Population422
    Treatment Seeking Population441
    Diagnosis Population452
    Prescription Population472
    Usage Patterns492
Global HIV Therapeutics Market: Europe Market5112
  Market Forecasts512
  Annual Cost of Therapy532
  Usage Patterns551
    Diseased Population551
    Treatment Seeking Population562
    Diagnosis Population582
    Prescription Population601
    Usage Patterns612
Global HIV Therapeutics Market: Japan Market639
  Market Forecasts632
  Annual Cost of Therapy651
  Usage Patterns661
    Diseased Population661
    Treatment Seeking Population671
    Diagnosis Population681
    Prescription Population691
    Usage Patterns702
Global HIV Therapeutics Market: Major Drug Classes7233
  Different Classes of Drugs721
    Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)721
    Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs)731
    Protease Inhibitors741
    Viral Fusion (or Entry) Inhibitors741
    HIV Integrase Strand Transfer Inhibitors741
    Multi-class Combination Products741
  Pipeline Analysis751
    Phase I768
    Phase II8413
    Phase III978
Global Hepatitis Therapeutics Market: Market Overview10512
  Introduction1051
  Revenue Forecasts for the Global Hepatitis Therapeutics Market1061
    Sales Value1061
    Annual Cost of Therapy1071
    Treatment Usage Patterns1082
      Diseased Population1101
      Treatment Seeking Population1111
      Diagnosed Population1121
      Prescription Population1131
  Hepatitis Market Drivers1141
    Hepatitis C is a Growing Market with Strong Competition and a Promising Pipeline1141
    Promising Developments in the Hepatitis C Pipeline1141
    Steady Increase in Prescription Population1141
  Hepatitis Market Restraints1151
    Hepatitis is Rarely Recognized During the Early Stages of the Disease Due to Lack of Symptoms During the Acute Phase1151
    Low Treatment Seeking Population1151
    Loss of Exclusivity Protection in Hepatitis B Market1151
  Generic Share in the Global Hepatitis Market1161
Global Hepatitis Market: Therapeutic Landscape11724
  Introduction1171
    Hepatitis A1171
    Hepatitis B1171
  Overview of Hepatitis A and B Vaccines Market1171
    Sales Value1181
  Hepatitis B Market1191
    Introduction1191
    Sales Value1201
    Annual Cost of Therapy1211
    Treatment Usage Patterns1221
      Diseased Population1231
      Treatment Seeking Population1241
      Diagnosed Population1251
      Prescription Population1261
    Geographical Segmentation1272
  Hepatitis C Market1291
    Introduction1291
    Sales Value1301
    Annual Cost of Therapy1311
    Treatment Usage Patterns1322
      Diseased Population1341
      Treatment Seeking Population1351
      Diagnosed Population1361
      Prescription Population1371
    Geographical Segmentation1383
Global Hepatitis Market: Geographical Landscape14150
  Geographical Break-up1413
  The US1441
    Sales Value1441
    Annual Cost of Therapy1451
    Treatment Usage Patterns1462
      Diseased Population1481
      Treatment Seeking Population1491
      Diagnosed Population1501
      Prescription Population1511
  Top Five Countries in Europe1521
    Sales Value1522
    Annual Cost of Therapy1541
    Treatment Usage Patterns1551
      Diseased Population1561
      Treatment Seeking Population1571
      Diagnosed Population1581
      Prescription Population1591
  Japan1601
    Sales Value1601
    Annual Cost of Therapy1611
    Treatment Usage Patterns1622
      Diseased Population1641
      Treatment Seeking Population1651
      Diagnosed Population1661
      Prescription Population1671
  Global Hepatitis Vaccines and Therapeutics Market: Pipeline Analysis1681
  Introduction1683
    Research and Development Pipeline Hepatitis B Therapeutics1715
    Research and Development Pipeline Hepatitis C Therapeutics17615
Herpes Simplex Therapeutics Market: Market Characterization19110
  Overview1911
  Herpes Simplex Therapeutics Market Size1921
  Herpes Simplex Therapeutics Market Forecast and CAGR1931
  Drivers and Barriers for the Herpes Simplex Therapeutics Market1941
    Drivers for the Herpes Simplex Therapeutics Market1941
    Barriers for the Herpes Simplex Therapeutics Market1941
  Herpes Simplex Therapeutics Market: Competitive Assessment1951
  Overview1951
  Strategic Competitor Assessment1951
  Product Portfolio for Major Marketed Products in the Herpes Simplex Therapeutics Market1961
    Zovirax (Acyclovir)1961
      Overview1961
      Efficacy1961
      Safety1961
      Clinical Study Details1961
    Famvir (Famciclovir)1971
      Overview1971
      Efficacy1971
      Safety1971
      Clinical Study Details1971
    Valtrex (Valacyclovir)1981
      Overview1983
Herpes Simplex Therapeutics Market: Pipeline Assessment2016
  Overview2011
  Herpes Simplex Therapeutics Promising Drugs under Clinical Development2011
  Molecule Profiles for Promising Drugs under Clinical Development2011
    BA-021 (Acyclovir Lauriad)2011
      Overview2011
      Efficacy2011
      Safety2011
      Clinical Study Details2011
    RPI-78M2021
      Overview2021
      Efficacy2021
      Safety2021
      Clinical Study Details2021
    AIC3162021
      Overview2021
      Efficacy2021
      Safety2021
      Clinical Study Details2021
  Herpes Simplex Therapeutics Market Pipeline Assessment by Mechanism of Action2031
  Herpes Simplex Therapeutics Market Pipeline Assessment by Clinical Phase of Development2041
    Herpes Simplex Therapeutics Phase III Clinical Pipeline2041
    Herpes Simplex Therapeutics Phase II Clinical Pipeline2051
    Herpes Simplex Therapeutics Phase I Clinical Pipeline2051
    Herpes Simplex Therapeutics Preclinical Pipeline2061
Global Influenza Therapeutics Market: Overview2072
  Disease Overview2071
  Influenza2071
  Market Overview2081
Global Influenza Therapeutics Market: Market Characterization2097
  Market Forecasts2091
  Annual Cost of Therapy2101
  Usage Patterns2111
    Diseased Population2111
    Treatment Seeking Population2121
    Diagnosis Population2131
    Usage Patterns2141
    Geographical Distribution2151
Global Influenza Therapeutics Market: The US Market2168
  Market Forecasts2161
  Annual Cost of Therapy2171
  Usage Patterns2181
    Diseased Population2181
    Treatment Seeking Population2191
    Diagnosis Population2201
    Prescription Population2211
    Usage Patterns2222
Global Influenza Therapeutics Market: Europe Market2248
  Market Forecasts2241
  Annual Cost of Therapy2251
  Usage Patterns2261
    Diseased Population2261
    Treatment Seeking Population2271
    Diagnosis Population2281
    Prescription Population2291
    Usage Patterns2302
Global Influenza Therapeutics Market: Japan Market2328
  Market Forecasts2321
  Annual Cost of Therapy2331
  Usage Patterns2341
    Diseased Population2341
    Treatment Seeking Population2351
    Diagnosis Population2361
    Prescription Population2371
    Usage Patterns2382
Pipeline Analysis2407
  Phase I2401
    CS-89582411
    GSK 2115160A2411
    Oseltamivir+Zanamivir2411
    Poly ICLC2411
    VAX128C2411
  Phase II2421
    ADS-89022421
    Chloroquine2421
    CSL-4122431
    DeltaFLU2431
    Fludase2431
    MVA-NP+M12431
    Oseltamivir2431
    TCAD Therapy2441

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets" Jan 31, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Antivirals-Market-to-2016-Antiretroviral-Agents-and-Combination-Therapies-to-be-Major-Drivers-HIV-and-Hepatitis-C-Markets-2115-159>
  
APA:
GBI Research Reports. (2011). Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets Jan 31, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Antivirals-Market-to-2016-Antiretroviral-Agents-and-Combination-Therapies-to-be-Major-Drivers-HIV-and-Hepatitis-C-Markets-2115-159>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.